Combination therapy for EGFR-mutated advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two oral drugs, sunvozertinib and anlotinib, taken together for people with advanced lung cancer that has an EGFR mutation and has gotten worse after EGFR targeted therapy. The goal is to see if this combination helps control cancer better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer is a type called non-squamous non-small cell (usually 'adenocarcinoma') and has spread locally or to other parts of the body.
- Your tumor has a specific EGFR gene change (like '19del', 'L858R', or 'T790M') that was found by an approved lab test.
- You have already had an EGFR targeted pill (like erlotinib, gefitinib, afatinib, or osimertinib) and either it stopped working or you had side effects that were too hard to handle.
- You are not able to or do not want to take standard chemotherapy, or your doctor says chemo is not right for you.
- You can do most daily activities (performance status 0 or 1) and have more than 12 weeks to live.
- You have at least one tumor that can be measured on a scan, and you do not have certain other gene changes (like RET, BRAF, NTRK, or MET) that would make this trial a bad fit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug sunvozertinib before and after surgery for non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). It aims to see if the drug can help shrink tumors and improve outcomes for patients whose cancer is at stage II, IIIA, or IIIB.
This study tests a combination of two oral targeted drugs—aumolertinib (which targets EGFR) and anlotinib (which blocks blood vessel growth to the tumor)—as a first treatment for advanced lung cancer that has both EGFR and TP53 mutations. It aims to see if the combination works better and is safe compared to standard care.
This trial tests a combination of two targeted pills (sunvozertinib and anlotinib) as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if this combination works better than current standard treatments.
This trial tests a combination of two oral drugs (sunvozertinib and anlotinib) as a first treatment for advanced lung cancer with certain EGFR mutations plus other gene changes. It aims to see if this combination works better than standard treatments.
This trial tests a drug called sunvozertinib in people with advanced non-small cell lung cancer (NSCLC) that has not been treated yet. It is for those who have certain uncommon changes in the EGFR gene. The drug may shrink tumors or stop them from growing.
This study tests a new pill called sunvozertinib in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to earlier treatments. The goal is to see how well it works and if it is safe.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.